Literature DB >> 10770636

Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors.

K Yazawa1, M Fujimori, J Amano, Y Kano, S Taniguchi.   

Abstract

A fundamental obstacle in gene therapy for cancer is the specific delivery of an anticancer gene product to a solid tumor, and yet no systemic delivery system that specifically targets solid tumors currently exists. A strain of domestic bacteria, Bifidobacterium longum, which is nonpathogenic and anaerobic, selectively localized and proliferated in several types of mouse solid tumors after systemic application. In this report, we further describe a novel approach to cancer gene therapy in which genetically engineered Bifidobacterium is used as a tumor-specific vector. Similarly to wild-type B. longum, genetically engineered B. longum could be detected in tumor tissue only and was not found in a large survey of normal mouse tissues after intravenous injection. This finding strongly suggests that obligate anaerobic bacteria such as Bifidobacterium can be used as highly specific gene delivery vectors for cancer gene therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10770636     DOI: 10.1038/sj.cgt.7700122

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  57 in total

1.  Can engineered bacteria help control cancer?

Authors:  R K Jain; N S Forbes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Sequence analysis of two cryptic plasmids from Bifidobacterium longum DJO10A and construction of a shuttle cloning vector.

Authors:  Ju-Hoon Lee; Daniel J O'Sullivan
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

Review 3.  The status of gene therapy for brain tumors.

Authors:  Giulia Fulci; E Antonio Chiocca
Journal:  Expert Opin Biol Ther       Date:  2007-02       Impact factor: 4.388

4.  Noninvasive imaging of infection after treatment with tumor-homing bacteria using Chemical Exchange Saturation Transfer (CEST) MRI.

Authors:  Guanshu Liu; Chetan Bettegowda; Yuan Qiao; Verena Staedtke; Kannie W Y Chan; Renyuan Bai; Yuguo Li; Gregory J Riggins; Kenneth W Kinzler; Jeff W M Bulte; Michael T McMahon; Assaf A Gilad; Bert Vogelstein; Shibin Zhou; Peter C M van Zijl
Journal:  Magn Reson Med       Date:  2013-10-07       Impact factor: 4.668

5.  Bifidobacterium breve as a delivery vector of IL-24 gene therapy for head and neck squamous cell carcinoma in vivo.

Authors:  L Wang; I Vuletic; D Deng; W Crielaard; Z Xie; K Zhou; J Zhang; H Sun; Q Ren; C Guo
Journal:  Gene Ther       Date:  2017-08-14       Impact factor: 5.250

6.  Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors.

Authors:  Michelle Cronin; David Morrissey; Simon Rajendran; Shereen M El Mashad; Douwe van Sinderen; Gerald C O'Sullivan; Mark Tangney
Journal:  Mol Ther       Date:  2010-04-13       Impact factor: 11.454

7.  Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104.

Authors:  Shie-Chau Liu; G-One Ahn; Mitomu Kioi; Mary-Jo Dorie; Adam V Patterson; J Martin Brown
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

8.  Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer.

Authors:  Clinton Yam; Ming Zhao; Katsuhiro Hayashi; Huaiyu Ma; Hiroyuki Kishimoto; Michele McElroy; Michael Bouvet; Robert M Hoffman
Journal:  J Surg Res       Date:  2009-03-31       Impact factor: 2.192

9.  Therapeutic efficacy of Bifidobacterium longum-mediated human interleukin-2 with endostatin or TRAIL in transplanted tumors in mice.

Authors:  Yan Yin; Lei Kou; Jian-Jun Wang; Gen-Xing Xu
Journal:  Exp Ther Med       Date:  2011-12-19       Impact factor: 2.447

10.  Targeted therapy of spinal cord glioma with a genetically modified Salmonella typhimurium.

Authors:  H Kimura; L Zhang; M Zhao; K Hayashi; H Tsuchiya; K Tomita; M Bouvet; J Wessels; R M Hoffman
Journal:  Cell Prolif       Date:  2009-11-18       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.